Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness

• Published in: Vaccine 2020-05, Vol.38 (26), p.4209-4218
• Main Authors: Hawksworth, Amy, Lockhart, Robert, Crowe, Jonathan, Maeso, Ruben, Ritter, Lydia, Dibben, Oliver, Bright, Helen
• Format: Article
• Language: English
• Subjects: Alveoli; Animals; Cell culture; Dogs; Epithelial cells; Fluorescence; Humans; Hypotheses; Infections; Infectivity; Influenza; Influenza A Virus, H1N1 Subtype - immunology; Influenza Vaccines; Influenza, Human - prevention & control; Madin Darby Canine Kidney Cells; Pandemics; Phenotypes; Potassium; Proteins; Replication; Strains (organisms); Tissue culture; Vaccine efficacy; Vaccines; Vaccines, Attenuated; Viruses
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2020.04.004

•H1N1 strains A/California/07/2009 and A/Bolivia/559/2013 are clinically suboptimal.•A/California/07/2009 and A/Bolivia/559/2013 have deficient multicycle infectivity.•Both strains have delayed replication in canine kidney cells versus pre-2009 strains.•The strains’ replicative fitness in human nasal epithelial cells is reduced.•Poor sustained replication of LAIV in human cells may cause reduced effectiveness. In the 2013–2014 and 2015–2016 influenza seasons, live attenuated influenza vaccine (LAIV) generated reduced vaccine effectiveness (VE) against circulating H1N1 strains. This reduced VE coincided with the introduction of pandemic 2009 H1N1 (A/H1N1pdm09) vaccine virus reassortants, in place of pre-2009 seasonal H1N1 strains. Here, we explored one specific hypothesis for reduced VE; decreased replicative fitness of A/H1N1pdm09 strains in humans. Two A/H1N1pdm09 strains with reduced VE, A/California/07/2009 (A/CA09) and A/Bolivia/559/2013 (A/BOL13), were compared to pre-2009 seasonal H1N1 strains, A/New Caledonia/20/1999 (A/NC99) and A/South Dakota/6/2007 (A/SD07). Initial results showed that A/H1N1pdm09 strains had reduced multi-cycle infectivity in Madin-Darby Canine Kidney (MDCK) cells, compared to their pre-2009 counterparts. The A/BOL13 viral titre was found to be 2.65 log10/mL lower when measured by multi-cycle 50% tissue culture infectious dose (TCID50) assay compared to single-cycle fluorescent focus assay (FFA). By contrast, clinically effective A/NC99 titres differed by only 0.54 log10/mL. In human alveolar (A549) cells, A/H1N1pdm09 strains replicated less than pre-2009 strains, with A/CA09 and A/BOL13 generating lower peak viral titres over 5 days. This phenotype was corroborated in physiologically relevant, primary human nasal epithelial cells (hNECs). Here, peak titres for pre-2009 strains A/NC99 and A/SD07 were 8.43 log10 TCID50/mL and 8.52 log10 TCID50/mL, respectively, versus 6.89 log10 TCID50/mL and 6.06 log10 TCID50/mL for A/H1N1pdm09 strains A/CA09 and A/BOL13. This confirmed a reduced ability of A/H1N1pdm09 strains to sustain replication in human respiratory cells. Using this information, H1N1 candidate A/Slovenia/2903/2015 (A/SLOV15) was characterised for replacement of A/BOL13 in the 2017/18 LAIV. A/SLOV15 produced comparable single and multi-cycle infectivity titres (Δ 0.16 log10/mL) and reached a peak titre 1.23 log10 TCID50/mL higher than that of A/BOL13 in hNEC cultures. Taken together, these data suggest a reduction in sustain